Covid-19 : quels sont les quatre nouveaux vaccins attendus cet automne ?

Covid-19 : quels sont les quatre nouveaux vaccins attendus cet automne ?

The peak of the 7th wave has largely passed, we are in the middle of summer and in August… Everything is ready for the Covid-19 vaccination rate to mark the time. Only 55,000 daily doses are administered, the vast majority second booster doses, that is, half that in mid-July.

The pace could pick up again at the start of the school year. The arrival of a probable 8th wave could encourage a certain number of inhabitants to reach out again. In addition, the High Health Authority could recommend a new booster dose for frail people, or even extend the objective to adults without comorbidities. Everything will depend in particular on the available vaccines, potentially more effective -especially against infection- than the messenger RNA ones (Pfizer/BioNTech or Moderna) currently used. Four new products are expected in September or October by the Ministry of Health, the latter indicated on July 20. Are here.

hipra

  • Technology : Recombinant protein vaccine.
  • Variants of which it is made: Alpha and Beta.
  • Efficiency : In a press release published on July 19, the Spanish firm assures that an “increase in neutralizing antibodies against Omicron BA.2, BA.4 and BA.5 was observed 14 days after the administration of the vaccine as a dose of booster in previously vaccinated participants” with two doses of the Pfizer/BioNTech or Moderna vaccine. We still do not have more precise efficacy rates, neither against infections nor against severe forms.
  • Advance : The European Commission announced on Tuesday that it had signed an agreement that allows it to acquire up to 250,000 doses of the vaccine developed by the Spanish firm. But first it will have to be authorized by the European Medicines Agency (EMA). The Hipra vaccine is still subject to a continuous review procedure, that is, the available data is analyzed in real time, without waiting for the presentation of a marketing authorization.

Sanofi

  • Technology : Recombinant protein vaccine.
  • Variants of which it is made: Parent strain of the virus and Beta variant.
  • Efficiency : In a press release published on June 24, the French group states that a booster dose of its vaccine has shown an efficacy of 72% (confidence interval between 45.8 and 86.6%) against symptomatic forms with the Omicron variant. In people who have already had Covid and therefore also benefit from the so-called “natural” immunity, this protection amounted to 93.2% (confidence interval between 73.2% and 99.2%). This study did not focus on the BA.5 sublineage of the Omicron variant, which is now the majority in France, but the efficacy of current vaccines appears similar against each member of the Omicron “family.”
  • Advance : Although its vaccine (developed with the British manufacturer GSK) has been under continuous review since July 2021, more than a year ago, Sanofi submitted a marketing authorization application to the EMA last March.

Pfizer/BioNTech adapted to Omicron

  • Technology : Messenger RNA vaccine.
  • Variants of which it is made: Original strain of the virus and Omicron variant (BA.1 initially).
  • Efficiency : This so-called “adapted” vaccine resulted in “significantly higher neutralizing antibody responses against Omicron BA.1” than the one currently in use, according to a June 25 Pfizer news release. On the other hand, the impact is less against BA.5 than against BA.1, with antibody titers three times lower. “This shortens the duration of protection compared to what it would be if the virus no longer evolved,” medical biologist Claude-Alexandre Gustave recently deciphered. The US Federal Drug Agency (FDA) has also asked messenger RNA manufacturers to also develop tailored versions of BA.5 and its “little brother” BA.4, in order to improve performance.
  • Advance : Pfizer and its partner BioNTech announced on July 19 that they had transmitted their data to the EMA. Three days later, he announced that his evaluation had begun.

Modern adapted to Omicron

  • Technology : Messenger RNA vaccine.
  • Variants of which it is made: Parent virus strain and variant Omicron BA.1 or BA.4/5.
  • Efficiency : Among participants who had never had Covid, the Omicron BA.1-adapted vaccine “resulted in significantly higher neutralizing titers against BA.4/5 compared to (the) currently licensed one,” Moderna advances in a press release published on July 11. After a month, these were almost double. In addition, this new vaccine “is generally well tolerated”, with no more side effects than the current one. As for the other bivalent vaccine candidate, based on the original strain of the virus and on the Omicron BA.5 variant this time, data are not yet available.
  • Advance : Like the one from Pfizer/BioNTech, Moderna’s adapted vaccines are officially under evaluation by the EMA since July 22.

#Covid19 #quels #sont #les #quatre #nouveaux #vaccins #attendus #cet #automne

Leave a Reply

Your email address will not be published.